Skip to main content

Table 1 Study population and comparison to full trial

From: Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study

Characteristic Genotyped Study
Cohort
N = 350
Full E2190/INT-0121
Cohort
N = 540
P-value1
  Median (IQR)2 Median (IQR)2  
Age 45 (39 to 50) 44 (38 to 50) 0.35
Axillary LN positive 14 (11 to 19) 14 (11 to 18) 0.13
Tumor size, cm 3.5 (2.1 to 5.0) 3.5 (2.1 to 5.0) 0.90
Median follow-up years 9.8 (8.3 to 11.2) 9.7 (8.1 to 11.4) 0.57
  Percent (95% CI) Percent (95% CI)  
Postmenopausal 31 (26 to 35) 29 (25 to 33) 0.22
Race - Caucasian 90 (87 to 93) 89 (86 to 91) 0.58
ER + 59 (54 to 64) 60 (56 to 64) 0.70
PR + 56 (51 to 61) 59 (54 to 63) 0.12
Lumpectomy 17 (13 to 20) 19 (15 to 22) 0.10
Treatment arm CAF+HDC 57 (51 to 62) 50 (47 to 54) <0.001
10-year DFS (%) 39 (34 to 44) 43 (38 to 47) 0.02
10-year OS (%) 45 (40 to 51) 48 (44 to 52) 0.09
  1. 1Pearson's chi-square test
  2. 2Interquartile range
  3. CAF: cyclophosphamide, doxorubicin fluorouracil; CI: confidence interval; DFS: disease free survival; ER: estrogen receptor; HDC: high dose chemotherapy; LN: lymph nodes; OS: overall survival; PR: progesterone receptor.